Evogene Ltd. (NASDAQ:EVGN) Q2 2024 Earnings Conference Call August 22, 2024 9:00 AM ET
Company Participants
Ofer Haviv - President and CEO
Yaron Eldad - CFO
Yoash Zohar - CEO, Casterra
Dan Jacob Gelvan - CEO, AgPlenus Ltd
Amit Noam - CEO, Lavie BIO
Conference Call Participants
Operator
Welcome to Evogene's Second Quarter Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded August 22, 2024.
Before we begin, I would like to caution that this presentation contains forward-looking statements relating to future events and Evogene Ltd., the company may, from time to time, make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, as amended.
Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, plan, estimated, intend and potential or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers: commercialization, efforts and timing, product development and launches, estimated market sizes and milestones, pipeline as well as our capabilities and technology.
Such statements are based on current expectations, estimates, projections and assumptions describe opinions about future events, involve certain risks and uncertainties, which are difficult to predict, and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel, such as further mobilizations or escalation in the northern border of Israel.
Those described in greater detail in Evogene's annual report on Form 20-F and in other information, Evogene files and furnishes with the Israel Securities Authority, and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.